• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's After-Market Session

    4/9/24 4:31:18 PM ET
    $APYX
    $ATXI
    $AVTX
    $CRVS
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APYX alert in real time by email

    Gainers

    • Jaguar Health (NASDAQ:JAGX) shares rose 25.3% to $0.11 during Tuesday's after-market session. The company's market cap stands at $31.1 million.
    • aTyr Pharma (NASDAQ:LIFE) shares rose 10.45% to $1.9. The company's market cap stands at $128.7 million.
    • Corvus Pharma (NASDAQ:CRVS) shares increased by 7.36% to $1.75. The market value of their outstanding shares is at $85.8 million.
    • ImmuCell (NASDAQ:ICCC) shares increased by 7.27% to $5.6. The market value of their outstanding shares is at $43.4 million.
    • Avenue Therapeutics (NASDAQ:ATXI) shares moved upwards by 6.46% to $0.16. The company's market cap stands at $6.9 million.
    • Xilio Therapeutics (NASDAQ:XLO) shares increased by 5.34% to $1.38. The company's market cap stands at $47.5 million.

    Losers

    • Apyx Medical (NASDAQ:APYX) shares declined by 6.1% to $1.38 during Tuesday's after-market session. The company's market cap stands at $47.8 million.
    • NKGen Biotech (NASDAQ:NKGN) shares decreased by 6.11% to $1.23. The market value of their outstanding shares is at $27.5 million.
    • Molecular Templates (NASDAQ:MTEM) shares decreased by 5.95% to $1.74. The market value of their outstanding shares is at $11.4 million.
    • Medigus (NASDAQ:MDGS) stock declined by 5.62% to $2.52. The company's market cap stands at $4.7 million.
    • Novo Integrated Sciences (NASDAQ:NVOS) shares declined by 5.18% to $0.5. The market value of their outstanding shares is at $8.9 million.
    • Avalo Therapeutics (NASDAQ:AVTX) stock fell 4.98% to $13.76. The company's market cap stands at $14.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APYX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APYX
    $ATXI
    $AVTX
    $CRVS

    CompanyDatePrice TargetRatingAnalyst
    Apyx Medical Corporation
    $APYX
    3/11/2026$6.00Neutral → Buy
    BTIG Research
    Ethos Technologies Inc.
    $LIFE
    2/23/2026$33.00Buy
    Goldman
    Ethos Technologies Inc.
    $LIFE
    2/23/2026$18.00Outperform
    Robert W. Baird
    Ethos Technologies Inc.
    $LIFE
    2/23/2026$21.00Mkt Outperform
    Citizens
    Ethos Technologies Inc.
    $LIFE
    2/23/2026$20.00Overweight
    Barclays
    Ethos Technologies Inc.
    $LIFE
    2/23/2026$23.00Buy
    Deutsche Bank
    Ethos Technologies Inc.
    $LIFE
    2/23/2026$13.00Overweight
    Analyst
    Ethos Technologies Inc.
    $LIFE
    2/23/2026$15.00Buy
    Citigroup
    More analyst ratings

    $APYX
    $ATXI
    $AVTX
    $CRVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Doyle Mittie

    4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

    3/18/26 4:07:19 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Senior Vice President Citronowicz Moshe exercised 37,000 shares at a strike of $1.80, increasing direct ownership by 8% to 493,504 units (SEC Form 4)

    4 - Apyx Medical Corp (0000719135) (Issuer)

    3/17/26 6:27:04 PM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    Director Micek John was granted 7,377 shares, increasing direct ownership by 13,919% to 7,430 units (SEC Form 4)

    4 - Jaguar Health, Inc. (0001585608) (Issuer)

    3/12/26 3:03:56 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APYX
    $ATXI
    $AVTX
    $CRVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board

    PORTLAND, Maine, March 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced that Kathy Turner has been appointed to its Board of Directors, effective April 1, 2026. Ms. Turner replaces Steven Rosgen, who is retiring from the Board after serving since January 2018. Upon joining the Board, Ms. Turner will serve as Chair of the Compensation and Stock Option Committee and as a member of the Audit Committee. Ms. Turner brings more than three decades of commercial executive leadership experience in global healthcar

    3/18/26 4:05:00 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting

    WALTHAM, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced an upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 17-22, 2026 at the San Diego Convention Center in San Diego, California. Poster presentation details, as follows: Title: Discovery and Optimization of XTX601, a Masked Claudin 18.2-Targeting T Cell EngagerSession Category: ImmunologySession Title: T Cell Engagers 1Session Date and Time: Monday, Apr. 20, 2026, from 9:00 a.m. to 12:0

    3/17/26 4:45:00 PM ET
    $XLO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

    NEW YORK, March 13, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that presentations from the Life Sciences Virtual Investor Forum, held March 11th – 12th, are now available for on-demand viewing. The forum featured CEO chats and company presentations from leadership teams representing innovative companies across the biotechnology, medical device, and pharmaceutical sectors, offering investors insights into emerging technologies, strategic initiatives, and growth opportunities within the life sciences industry. REGISTER AND VIEW PRESENTATIONS HERE The presentations will be available 24/7 for 90 days. Investors,

    3/13/26 8:35:00 AM ET
    $AEMD
    $CVKD
    $DYAI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    $APYX
    $ATXI
    $AVTX
    $CRVS
    SEC Filings

    View All

    ImmuCell Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - IMMUCELL CORP /DE/ (0000811641) (Filer)

    3/18/26 4:05:54 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form PRE 14A filed by Jaguar Health Inc.

    PRE 14A - Jaguar Health, Inc. (0001585608) (Filer)

    3/13/26 4:59:50 PM ET
    $JAGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corvus Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)

    3/13/26 8:46:18 AM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APYX
    $ATXI
    $AVTX
    $CRVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Apyx Medical upgraded by BTIG Research with a new price target

    BTIG Research upgraded Apyx Medical from Neutral to Buy and set a new price target of $6.00

    3/11/26 8:28:33 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    Goldman initiated coverage on Ethos Technologies with a new price target

    Goldman initiated coverage of Ethos Technologies with a rating of Buy and set a new price target of $33.00

    2/23/26 8:37:19 AM ET
    $LIFE
    Specialty Insurers
    Finance

    Robert W. Baird initiated coverage on Ethos Technologies with a new price target

    Robert W. Baird initiated coverage of Ethos Technologies with a rating of Outperform and set a new price target of $18.00

    2/23/26 8:37:19 AM ET
    $LIFE
    Specialty Insurers
    Finance

    $APYX
    $ATXI
    $AVTX
    $CRVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Botha Roelof bought $4,949,975 worth of shares (260,525 units at $19.00), converted options into 12,000,124 shares and returned 12,000,124 shares to the company (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    2/2/26 6:36:37 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Director Wheeler William J bought $4,949,975 worth of shares (260,525 units at $19.00), increasing direct ownership by 2,481% to 271,025 units (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    1/30/26 8:49:26 PM ET
    $LIFE
    Specialty Insurers
    Finance

    Director Mullin Mark W. bought $99,997 worth of shares (5,263 units at $19.00), increasing direct ownership by 43% to 17,451 units (SEC Form 4)

    4 - Ethos Technologies Inc. (0001788451) (Issuer)

    1/30/26 8:48:09 PM ET
    $LIFE
    Specialty Insurers
    Finance

    $APYX
    $ATXI
    $AVTX
    $CRVS
    Financials

    Live finance-specific insights

    View All

    Apyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial Results

    Reported record total revenue of $19.2 million in the fourth quarter of 2025Scaling U.S. commercial launch of AYON Body Contouring System™ (AYON) to meet strong market demandExpect FY2026 total revenue in the range of $57.5 million to $58.5 millionManagement to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., March 10, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its fourth quarter and full year ended December 31, 2025. Recent Financial and Operating Highlights: Reported

    3/10/26 7:00:00 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

    SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 12, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter 2025 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 d

    3/5/26 4:01:00 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025

    PORTLAND, Maine, March 04, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today announced its unaudited financial results for the year ended December 31, 2025. Management's Discussion: "Today we are reporting 2025 net operating income of $1.6 million, an increase of $3.3 million compared to 2024. These results were largely driven by a significant improvement in gross margin, reflecting higher volumes, manufacturing efficiencies, and price realization," commented Timothy C. Fiori, Chief Financial Officer of ImmuCell. "Net loss

    3/4/26 4:05:00 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $APYX
    $ATXI
    $AVTX
    $CRVS
    Leadership Updates

    Live Leadership Updates

    View All

    ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board

    PORTLAND, Maine, March 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (NASDAQ:ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced that Kathy Turner has been appointed to its Board of Directors, effective April 1, 2026. Ms. Turner replaces Steven Rosgen, who is retiring from the Board after serving since January 2018. Upon joining the Board, Ms. Turner will serve as Chair of the Compensation and Stock Option Committee and as a member of the Audit Committee. Ms. Turner brings more than three decades of commercial executive leadership experience in global healthcar

    3/18/26 4:05:00 PM ET
    $ICCC
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board

    SANTA ANA, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics, today announced the appointment of Bruce L. Miller, M.D. to its Scientific Advisory Board. Dr. Miller is internationally recognized for his leadership in Alzheimer's disease ("AD"), frontotemporal dementia ("FTD"), and other neurocognitive disorders, and brings extensive scientific and clinical expertise to the Company. Dr. Miller is the A.W. and Mary Margaret Clausen Distinguished Professor in Neurology at the U

    1/22/26 8:05:00 AM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    NKGen Biotech, Inc. Issues Statement on Recent Board Appointments at Majority-Owned Korean Affiliate NKGen Korea Co., Ltd.

    SANTA ANA, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ("NK") cell therapeutics and the majority owner of NKGen Biotech Korea Co., Ltd. ("NKGen Korea"), today issued the following statement regarding recent changes to the NKGen Korea Board of Directors (the "NKGen Korea Board"). NKGen Korea, formerly NKMax Co., Ltd., recently completed a shareholder-approved name change on November 21, 2025. On this date, NKGen Korea also announced through its official KOSDAQ disclosures the appointment of th

    12/3/25 8:05:00 AM ET
    $NKGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APYX
    $ATXI
    $AVTX
    $CRVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Molecular Templates Inc.

    SC 13G/A - Molecular Templates, Inc. (0001183765) (Subject)

    11/18/24 9:49:56 PM ET
    $MTEM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Avenue Therapeutics Inc.

    SC 13D/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)

    11/15/24 4:05:50 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Avalo Therapeutics Inc.

    SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

    11/14/24 6:23:00 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care